Table 1.
Characteristics |
Intervention (n=81) |
Placebo (n=78) |
P Value for Difference |
---|---|---|---|
Age at randomization, mean (SD), y | 61.3 (7.2) | 60.7 (6.6) | .56a |
Race/ethnicity, No. (%) | |||
White | 71 (88) | 70 (90) | .82b,c |
African American | 6 (7) | 5 (7) | .91b,d |
Hispanic | 1 (1) | 1 (1) | |
Asian | 1 (1) | 1 (1) | |
Other (including Pacific Islander) | 2 (3) | 1 (1) | |
Weight, mean (SD), kg | 87.1 (13.4) | 88.9 (14.8) | .36a |
Height, mean (SD), cm | 177.4 (7.1) | 178.6 (8.4) | .31a |
BMIe | |||
Mean (SD) | 27.6 (3.6) | 27.9 (4.2) | .64a |
Median (IQR) | 27.4 (3.90) | 27.4 (5.58) | .91b |
Serum total cholesterol level, mean (SD), mg/dLf | 183.4 (29.8) | 187.4 (36.9) | .48a |
High-risk characteristics | |||
Preoperative PSA level, ng/mL | |||
Mean (SD) | 7.13 (3.87) | 7.71 (4.20) | .36a |
Median (IQR) | 5.90 (3.20) | 6.62 (3.98) | .21g |
Gleason score, mean (SD) | 7.00 (0.82) | 7.01 (0.80) | .98g |
5 | 1 (1) | 0 | .78b,h |
6 | 19 (23) | 18 (23) | |
7 | 45 (56) | 47 (60) | |
8 | 11 (14) | 7 (9) | |
9 | 5 (6) | 6 (8) | |
Positive surgical margins, No. (%) | 38 (47) | 27 (35) | .15i |
Extracapsular extension, No. (%) | 54 (67) | 61 (78) | .11i |
Positive seminal vesicle(s), No. (%) | 15 (19) | 12 (15) | .68i |
Lymph node metastases, No./examined | 0/36 | 2/31 | .50i |
High-risk characteristics, mean (SD), No. | 1.54 (0.78) | 1.50 (0.75) | .72a |
1 | 48 (59) | 8 (62) | .87bj |
≥2 | 33 (41) | 30 (38) |
Abbreviations: BMI, body mass index, calculated as weight in kilograms divided by height in meters squared; IQR, interquartile range; PSA, prostate-specific antigen.
SI conversion: To convert total cholesterol to mmol/L, multiply by 0.0259.
By t test.
By χ2 test.
White vs all others.
White vs African American vs all others.
Calculated in 81 intervention participants and 77 placebo participants.
Calculated in 74 intervention participants and 76 placebo participants.
By Mann-Whitney test.
Score of 5 or 6 vs 7 vs 8 vs 9.
By Fisher exact test.
None vs 1 vs 2.